gabexate has been researched along with Dyspepsia in 3 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 9.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "Camostat mesilate is superior to famotidine for relieving epigastralgia in patients with functional dyspepsia." | 9.12 | Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective? ( Ashizawa, N; Hashimoto, T; Imaoka, T; Kinoshita, Y; Miyake, T; Shizuku, T, 2006) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 7.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease." | 5.14 | Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. ( Inami, K; Kubokawa, Y; Matsumura, Y; Sai, JK; Suyama, M; Watanabe, S, 2010) |
| "Camostat mesilate is superior to famotidine for relieving epigastralgia in patients with functional dyspepsia." | 5.12 | Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective? ( Ashizawa, N; Hashimoto, T; Imaoka, T; Kinoshita, Y; Miyake, T; Shizuku, T, 2006) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 3.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamawaki, H | 1 |
| Futagami, S | 1 |
| Kaneko, K | 1 |
| Agawa, S | 1 |
| Higuchi, K | 1 |
| Murakami, M | 1 |
| Wakabayashi, M | 1 |
| Sakasegawa, N | 1 |
| Kodaka, Y | 1 |
| Ueki, N | 1 |
| Gudis, K | 1 |
| Kawamoto, C | 1 |
| Iwakiri, K | 1 |
| Sai, JK | 1 |
| Suyama, M | 1 |
| Kubokawa, Y | 1 |
| Matsumura, Y | 1 |
| Inami, K | 1 |
| Watanabe, S | 1 |
| Ashizawa, N | 1 |
| Hashimoto, T | 1 |
| Miyake, T | 1 |
| Shizuku, T | 1 |
| Imaoka, T | 1 |
| Kinoshita, Y | 1 |
2 trials available for gabexate and Dyspepsia
| Article | Year |
|---|---|
Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease.
Topics: Abdominal Pain; Adult; Aged; Dyspepsia; Endosonography; Esters; Female; Gabexate; Guanidines; Humans | 2010 |
Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?
Topics: Anti-Ulcer Agents; Dyspepsia; Esters; Famotidine; Female; Gabexate; Guanidines; Humans; Japan; Male; | 2006 |
1 other study available for gabexate and Dyspepsia
| Article | Year |
|---|---|
Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
Topics: Abdominal Pain; Aged; Benzamides; Drug Therapy, Combination; Dyspepsia; Esters; Female; Gabexate; Ga | 2019 |